Inactive Instrument

Press Releases Kadimastem Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0011284614

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	02-28	AQ
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	02-28	AQ
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	02-16	AQ
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	02-07	AQ
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	01-25	AQ
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	01-22	AQ
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	11-07	AQ
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	20/06/23	AQ
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	09/03/21	PR
Kadimastem : Announces Executive Management Changes	01/02/21	PR
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	16/12/20	AQ
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	03/08/20	PR
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS	06/01/20	PR
Kadimastem : Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients	23/12/19	PR
Kadimastem : Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results	18/11/19	PR
Kadimastem : to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel	11/11/19	PR
Kadimastem : Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS	24/09/19	PR
Kadimastem : Announces Leadership Changes	29/05/19	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer